Marquia Edwards
Real-World Comparison of sofosbuvir/velpatasvir (Epclusa) vs. glecaprevir/pibrentasvir (Mavyret) in an FQHC Population

Hepatitis C care isn’t just about the medication—it’s about access, support, and helping patients succeed in the real world.
This project means a lot to me because it focuses on real-world hepatitis C care — looking at how adherence and access impact treatment success in underserved communities. Grateful for the opportunity to highlight the work happening in FQHCs and to keep pushing for better outcomes for every patient!
I’m truly honored and grateful to have received the incentive grant in support of my research project. I’m especially excited for the opportunity to work with mentors who can guide me and share their expertise and advice. This recognition reinforces the importance of improving medication access, adherence support, and individualized care to optimize hepatitis C treatment outcomes in underserved communities.
